Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Current Leases (2019 - 2025)

Dexcom (DXCM) has disclosed Current Leases for 7 consecutive years, with $21.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Leases fell 4.0% to $21.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $21.6 million, a 4.0% decrease, with the full-year FY2025 number at $21.6 million, down 4.0% from a year prior.
  • Current Leases was $21.6 million for Q4 2025 at Dexcom, down from $23.6 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $23.6 million in Q3 2025 to a low of $18.2 million in Q1 2021.
  • A 5-year average of $21.2 million and a median of $21.2 million in 2022 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: rose 25.52% in 2021, then decreased 6.76% in 2024.
  • Dexcom's Current Leases stood at $20.5 million in 2021, then changed by 0.0% to $20.5 million in 2022, then rose by 2.93% to $21.1 million in 2023, then rose by 6.64% to $22.5 million in 2024, then fell by 4.0% to $21.6 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Current Leases are $21.6 million (Q4 2025), $23.6 million (Q3 2025), and $23.4 million (Q2 2025).